Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

OBJECTIVE: To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. METHODS: We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indire...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar, Pedro Nazareth, Tan, Pui San, Simko, Sarah, Barreto, Carmelia Maria Noia, Gutierres, Bárbara de Souza, del Giglio, Auro, Lopes, Gilberto de Lima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2019
Materias:
Health Economics and Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394999/
https://www.ncbi.nlm.nih.gov/pubmed/30843996
http://dx.doi.org/10.31744/einstein_journal/2019GS4414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394999/
https://www.ncbi.nlm.nih.gov/pubmed/30843996
http://dx.doi.org/10.31744/einstein_journal/2019GS4414

Ejemplares similares